Given that the SARS-CoV-2 infection does increase the pro-inflammatory cytokines level (Liu et al., 2020), the combined effect of these medications on DUSP1 and DUSP5 expression might play a significant role in attenuating the immunopathology of COVID-19. Here, DUSP5 is linked to COVID-19.